Sterilization Modality Selection: Role of Sterility Assurance Subject Matter Expert.


Journal

Biomedical instrumentation & technology
ISSN: 0899-8205
Titre abrégé: Biomed Instrum Technol
Pays: United States
ID NLM: 8905560

Informations de publication

Date de publication:
01 Mar 2021
Historique:
entrez: 21 6 2021
pubmed: 22 6 2021
medline: 24 6 2021
Statut: ppublish

Résumé

Selection of a sterilization modality for a medical device is a critical decision that requires sterility assurance subject matter experts (SME)s to work collaboratively with various company functions. The sterility assurance SME is responsible and accountable for the sterilization modality decision for a product. The modality selection process starts with the sterility assurance SME partnering with research and development to ensure that the sterilization modality allows the device to deliver its intended function in patient care. After the sterilization modality is selected, the sterility assurance SME needs to work with other partners, including quality, supply chain/logistics, operations, and regulatory, to ensure that the selected sterilization modality is appropriately integrated into the end-to-end process. Collaborative partnerships between sterility assurance experts and key partners regarding sterilization modality selection reduce the potential for negative impacts within the end-to-end sterility assurance process, including impacts on product functionality, increased regulatory approval timelines, and inefficiencies and risks throughout the supply chain. This article describes aspects of a comprehensive approach to sterilization modality selection, including critical information necessary to address each of the key considerations.

Identifiants

pubmed: 34153991
pii: 465982
doi: 10.2345/0899-8205-55.s3.67
pmc: PMC8655698
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

67-77

Informations de copyright

© Copyright AAMI 2021. Copying, networking, and distribution prohibited.

Références

Biomed Instrum Technol. 2020 Jun 1;54(s1):6-14
pubmed: 34169981

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH